Candriam S.C.A. Aldeyra Therapeutics, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALDX
# of Institutions
116Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$39.6 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$23.4 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$16.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$15.5 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$8.03 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $249M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...